Data gathered: March 5
AI Stock Analysis - Verve Therapeutics (VERV)
Analysis generated March 4, 2025. Powered by Chat GPT.
Verve Therapeutics is a biotechnology company committed to developing innovative therapies for cardiovascular diseases. The company's approach leverages gene editing technology to target key elements that cause conditions such as hypercholesterolemia. With a strong foundation in cutting-edge research, Verve Therapeutics aims to transform the standard of care for cardiovascular diseases.
Stock Alerts - Verve Therapeutics (VERV)
 |
Verve Therapeutics | March 5 Price is up by 6.9% in the last 24h. |
|
Verve Therapeutics | March 4 Price is down by -5% in the last 24h. |
|
Verve Therapeutics | March 4 Employee Rating is up by 2.4% over the last month. |
|
Verve Therapeutics | February 25 Price is down by -5.5% in the last 24h. |
Alternative Data for Verve Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,736 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,892 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 303 | Sign up | Sign up | Sign up |
About Verve Therapeutics
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
| Price | $6.55 |
| Target Price | Sign up |
| Volume | 1,610,000 |
| Market Cap | $548M |
| Year Range | $4.4 - $8.63 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
What is William Blair’s Forecast for VERV Q1 Earnings?March 3 - ETF Daily News |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 3 - Finnhub |
|
 |
Verve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst SaysMarch 2 - ETF Daily News |
 |
Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2February 27 - SeekingAlpha |
 |
Verve Therapeutics reports Q4 EPS (58c), consensus (67c)February 27 - Thefly.com |
Verve Therapeutics: Q4 Earnings SnapshotFebruary 26 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 6.9M | 14M | -14M | -50M | -55M | -0.590 |
| Q2 '24 | 6.7M | 15M | -15M | -50M | -57M | -0.590 |
| Q1 '24 | 5.7M | 18M | -19M | -49M | -55M | -0.590 |
| Q4 '23 | 7.3M | 16M | -8.3M | -48M | -52M | -0.690 |
| Q3 '23 | 3.1M | 12M | -12M | -46M | -51M | -0.720 |
Insider Transactions View All
| Dorval Allison filed to sell 5,380 shares at $5.6. December 3 '24 |
| Ashe Andrew D. filed to buy 342,509 shares at $6.3. May 15 '24 |
| Nickerson Joan filed to sell 8,659 shares at $8.2. April 3 '24 |
| Yeshwant Krishna filed to buy 1,800,000 shares at $10. December 5 '23 |
| Dorval Allison filed to sell 4,060 shares at $11.5. December 1 '23 |
Similar companies
Read more about Verve Therapeutics (VERV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Verve Therapeutics?
The Market Cap of Verve Therapeutics is $548M.
What is the current stock price of Verve Therapeutics?
Currently, the price of one share of Verve Therapeutics stock is $6.55.
How can I analyze the VERV stock price chart for investment decisions?
The VERV stock price chart above provides a comprehensive visual representation of Verve Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Verve Therapeutics shares. Our platform offers an up-to-date VERV stock price chart, along with technical data analysis and alternative data insights.
Does VERV offer dividends to its shareholders?
As of our latest update, Verve Therapeutics (VERV) does not offer dividends to its shareholders. Investors interested in Verve Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Verve Therapeutics?
Some of the similar stocks of Verve Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.